Skip to content
Peptide Atlas
All peptides

Linaclotide

Tier 1 · Human trials
Also known as Linzess · Constella · MD-1100

Strongest evidence is Tier 1: multiple randomized controlled trials and FDA/EMA-approved human indications for IBS-C and chronic idiopathic/functional constipation. Numerous mechanistic, energy-expenditure, colorectal-cancer-prevention, and TMAO claims rest only on animal, in vitro, or theoretical evidence (Tier 2/4), and pediatric efficacy data are limited (no published placebo-controlled trials in children per one review).

Half-life
~0.05 h
Routes
Oral
Goals
Digestive health / constipation relief · IBS symptom management
Cost / mg
Not recorded

How it works

Linaclotide is a small 14-amino-acid peptide that mimics the body's natural guanylin hormones. Taken by mouth, it stays inside the gut and switches on a receptor called guanylate cyclase-C (GC-C) on the lining of the intestine. This raises a signaling molecule called cGMP, which prompts the gut to secrete chloride, bicarbonate, and fluid into the intestine. The extra fluid softens stool and speeds up movement through the bowel, relieving constipation. The rise in cGMP also appears to reduce gut pain signaling, which helps with the abdominal pain and bloating of IBS-C. Because it is barely absorbed into the bloodstream, its effects are almost entirely local to the intestine.

Overview

Overview

Linaclotide (marketed as Linzess and Constella; development code MD-1100) is a first-in-class, orally administered guanylate cyclase-C (GC-C) agonist. It is a 14-amino-acid peptide of the guanylin peptide family and a structural analog of guanylin, engineered to be protease-resistant and acid-stable so it survives the gut environment. It was approved by the U.S. FDA on August 30, 2012 (initial U.S. approval 2012) and by the European Medicines Agency for moderate-to-severe IBS-C.

Approved Uses

  • Irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older.
  • Chronic idiopathic constipation (CIC) in adults.
  • Functional constipation (FC) in pediatric patients — the FDA prescribing information states 2 years of age and older, while one manufacturer source cites 6 years and older (see the caveats note; sources disagree on the minimum pediatric age).

IBS-C and CIC are common conditions, with combined estimates affecting roughly 20% of the general population; chronic constipation prevalence is cited around 14–15% and IBS around 5–12% in North America.

How It Works

Linaclotide binds GC-C receptors on the luminal surface of intestinal enterocytes, raising intracellular and extracellular cGMP. This activates the CFTR channel and drives secretion of chloride, bicarbonate, and fluid into the intestinal lumen, increasing intestinal fluid and accelerating transit. Elevated extracellular cGMP is also thought to reduce visceral pain signaling, which is reflected in improvements in the abdominal pain and bloating of IBS-C. The drug has negligible oral bioavailability and acts locally, with minimal systemic exposure.

Clinical Evidence

  • In IBS-C, a 12-week RCT of linaclotide 290 mcg daily (800 patients) achieved the FDA endpoint with P<0.0001 and a number needed to treat of 8, improving both abdominal symptoms (pain, bloating) and bowel symptoms.
  • In chronic constipation, two RCTs (1,272 patients total) used a primary outcome of ≥3 complete spontaneous bowel movements (CSBMs) per week plus an increase of ≥1 CSBM/week from baseline for ≥9 of 12 weeks.
  • A network meta-analysis (33 RCTs, 17,214 patients) found linaclotide 290 µg once daily had similar efficacy to prucalopride 2 mg once daily (P-score 0.76).
  • A randomized placebo-controlled study in women with constipation-predominant IBS reported faster time to first bowel movement, increased stool frequency, softer stool, easier passage, and accelerated ascending colonic transit.
  • Strong guideline recommendations, based on high-level evidence, support use for CIC in adults. Linaclotide is generally positioned as a secretagogue/prosecretory agent for chronic constipation after lifestyle changes and traditional laxatives.

Emerging and Investigational Directions

Several additional uses rest on animal, in vitro, or theoretical evidence only and are not established human indications: brown-fat thermogenesis and increased energy expenditure via hypothalamic GUCY2C, colorectal cancer prevention via a GUCY2C/cGMP/PKG tumor-suppressor axis, and reduction of the cardiovascular/renal-associated metabolite TMAO. Observational reports also describe promise in refractory lower-GI manifestations of systemic sclerosis and in constipation from opioids, diabetes, neurological conditions, and post-surgical states. Pediatric efficacy evidence is limited — one review notes no published placebo-controlled trials in children.

What the research shows

189 findings extracted from the 29 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 12 human trial findings, 3 human study findings and 4 expert opinion findings.

  • human trialHigher dosage (290 mcg daily) not associated with additional clinical benefit for chronic idiopathic constipation9

  • human trialA 12-Week, Randomized, Controlled Trial showed linaclotide at 290 micrograms daily achieved FDA endpoint with P value < 0.0001 and NNT of 8 in IBS-C11

  • human trialStudy included 800 patients randomized to placebo (395) or linaclotide (405)11

  • human trialOther primary outcomes and secondary outcomes appear to show statistical significance favoring linaclotide in IBS-C11

  • human trialTwo Randomized Trials of Linaclotide for Chronic Constipation enrolled 1272 patients in intent-to-treat analysis (642 in Trial 303 and 630 in Trial 01)11

  • human trialPrimary outcome was three or more complete spontaneous bowel movement (CSBMs) per week and an increase of at least one CSBM per week from baseline for 9 or more weeks during the 12-week treatment period11

  • human trialLinaclotide improves abdominal symptoms (pain, bloating) and bowel symptoms (constipation) compared with placebo in patients with IBS-C13

  • human trialStrong recommendation made for the use of linaclotide for CIC in adults based on available evidence16

Show the remaining 11

  • human trialStrong recommendation for the use of linaclotide for CIC in adults based on available evidence17

  • human trialLinaclotide 290 μg once daily had similar efficacy to prucalopride 2 mg once daily for failure to achieve an increase of one or more CSBM per week from baseline at 12 weeks19

  • human trialLinaclotide 290 μg once daily ranked with a P-score of 0.76 for the endpoint of failure to achieve an increase of one or more CSBM per week from baseline at 12 weeks19

  • human trialOne randomized, double-blind, placebo-controlled study of linaclotide in female patients with C-IBS reported significant treatment effects on time to first bowel movement, increase of stool frequency, decrease of stool consistency, improvement of ease of stool passage, and accelerated ascending colonic transit time23

  • human studyBenefits and cautions of linaclotide have been described through meta-analysis of treatment options for functional constipation15

  • human studyTo date, there are no placebo-controlled trials published on the use of linaclotide or lubiprostone in children.21

  • human studyEvidence for the role of linaclotide in chronic constipation shows increasing data on its efficacy in improving bowel habits, ameliorating bowel symptoms, improving quality of life, and without associated serious adverse events23

  • expert opinionLinaclotide (Linzess) was approved in August 2012 for the treatment of IBS–C and CIC in adults7

  • expert opinionLinaclotide has a high level of evidence for treatment of chronic constipation18

  • expert opinionLinaclotide should be offered as a treatment option for chronic idiopathic constipation alongside other prosecretory agents and 5-HT4 receptor agonists when patients do not respond to lifestyle modifications and traditional laxatives20

  • expert opinionSlow-transit constipation is best treated with laxatives such as polyethylene glycol or newer agents such as linaclotide or lubiprostone22

How it works

Based on 4 human trial findings, 1 human study finding, 7 animal findings, 17 expert opinion findings and 5 theoretical findings.

  • human trialIt works by increasing intestinal fluid secretion, which helps ease the passage of stools and relieve the symptoms of constipation8

  • human trialLINZESS increases fluid secretion and GI motility12

  • human trialLINZESS is a peptide that stimulates the GC-C receptor12

  • human trialLINZESS binds to the guanylate cyclase-C (GC-C) receptor resulting in an increase in intracellular & extracellular concentrations of cGMP, which stimulates secretion of chloride and bicarbonate into the intestinal lumen, resulting in increased intestinal fluid and accelerated transit12

  • human studyThere was no age-dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age12

  • animalIn animal studies, activation of guanylate cyclase 2C receptors by orally administered linaclotide stimulates the sympathetic nervous system, leading to thermogenesis of brown fat and increased energy expenditure5

  • animalLinaclotide inhibits the absorption of sodium, leading to fluid retention and increased fluidity of intestinal contents, improving GI transit in cystic fibrosis model of mice5

  • animalLinaclotide decreased trimethylamine-N-oxide (TMAO), a hepatic metabolic product associated with cardiovascular disease and kidney dysfunction progression5

Show the remaining 26

  • animalLinaclotide acts through elevation of cyclic guanosine monophosphate (cGMP) levels13

  • animalLinaclotide leads to accelerated gastrointestinal (GI) transit through increased fluid secretion13

  • animalLinaclotide reduces visceral hypersensitivity13

  • animalIn animal studies, activation of guanylate cyclase 2C receptors in the mediobasal hypothalamic region by linaclotide stimulates the sympathetic nervous system, leading to thermogenesis of brown fat14

  • expert opinionDrug lacks typical characteristics of a molecule that is likely to undergo uptake into maternal milk such as high maternal plasma concentrations, lipid solubility, low molecular weight1

  • expert opinionLINZESS is a guanylate cyclase-C agonist2

  • expert opinionLinaclotide acts as a guanylate cyclase-C agonist4

  • expert opinionLinaclotide is a potent and highly selective agonist of guanylate cyclase-C (GC-C) receptors in the intestine5

  • expert opinionLinaclotide is a first-in-class, 14-amino acid peptide of the guanylin peptide family7

  • expert opinionLinaclotide acts as a selective agonist at the guanylate cyclase–C (GC–C) receptor on the luminal surface of intestinal enterocytes7

  • expert opinionActivation of GC–C by guanylin peptides, including linaclotide, results in increased levels of cyclic g7

  • expert opinionLinaclotide is a guanylate cyclase-C (GC-C) agonist that stimulates secretion of chloride and bicarbonate into intestinal lumen, which increases intestinal fluid and accelerates intestinal transit9

  • expert opinionLinaclotide is a protease-resistant, acid-stable, 14–amino acid peptide10

  • expert opinionLinaclotide is a first-in-class medication that stimulates guanylyl cyclase C (GC-C) receptors10

  • expert opinionCyclic GMP (cGMP) helps regulate multiple essential functions throughout the body, including blood pressure, long bone growth, and lipolysis; more crucial to the gut, it also regulates intestinal fluid secretion and visceral pain10

  • expert opinionGuanylyl cyclase catalyzes the conversion of guanosine triphosphate to cGMP10

  • expert opinionLinaclotide is a guanylate cyclase-C (GC-C) agonist11

  • expert opinionWhen the GC-C agonist binds to the receptors on the luminal surface, intracellular and extracellular levels of cyclic guanosine monophosphate (cGMP) is increased11

  • expert opinionIncrease levels of cGMP encourage the release of chloride and bicarbonate into the intestinal lumen; this causes an increase in intestinal fluid and more rapid transit11

  • expert opinionLinaclotide is a potent and highly selective agonist of guanylate cyclase-C (GC-C) receptors in the intestine14

  • expert opinionIBS aetiopathogenesis and pathophysiological mechanism are unknown27

  • theoreticalGuanylate cyclase C (GUCY2C) behaves as a tumor suppressor in the intestine, and replacement therapy with GUCY2C ligand has been proposed as a strategy for preventing colorectal cancer5

  • theoreticalLinaclotide is a guanylate cyclase C agonist (GCCA)13

  • theoreticalLinaclotide is a first-in-class guanylate cyclase-C agonist that activates CFTR, leading to increased intestinal chloride, bicarbonate, and fluid secretion23

  • theoreticalLinaclotide activates the receptor guanylate cyclase-C located on the luminal membrane of enterocytes, resulting in an increase of intracellular second messenger cyclic guanosine monophosphate, which ultimately results in activation of CFTR23

  • theoreticalLinaclotide is a structural analog of guanylin and is an agonist for the GC-C receptor when administered orally23

Dosing

Based on 18 human trial findings and 3 expert opinion findings.

  • human trialRecommended dosage for IBS-C in adults is 290 mcg orally once daily2

  • human trialRecommended dosage for CIC in adults is 145 mcg orally once daily or 72 mcg orally once daily based on individual presentation or tolerability2

  • human trialRecommended dosage for pediatric patients 7 years and older with IBS-C is 145 mcg orally once daily2

  • human trialRecommended dosage for pediatric patients 2 years and older with FC is 72 mcg orally once daily2

  • human trialLINZESS should be taken on empty stomach at least 30 minutes prior to a meal at approximately the same time each day2

  • human trialRecommended dosage for IBS-C in adults is 290 mcg orally once daily3

  • human trialRecommended dosage for CIC in adults is 145 mcg orally once daily or 72 mcg orally once daily based on individual presentation or tolerability3

  • human trialRecommended dosage for pediatric patients 7 years of age and older with IBS-C is 145 mcg orally once daily3

Show the remaining 13

  • human trialRecommended dosage for pediatric patients 2 years of age and older with FC is 72 mcg orally once daily3

  • human trialTake on empty stomach at least 30 minutes prior to a meal at approximately the same time each day3

  • human trialDo not crush or chew LINZESS capsule or capsule contents3

  • human trialTake this medicine on an empty stomach, at least 30 minutes before breakfast or the first meal of the day8

  • human trialSwallow the capsule whole. Do not crush, break, or chew it8

  • human trialLinaclotide 290 mcg once daily is the dose for IBS with constipation9

  • human trialLinaclotide 145 mcg once daily is the dose for chronic idiopathic constipation9

  • human trialLinaclotide 72 mcg once daily may be used for chronic idiopathic constipation based on individual presentation or tolerability9

  • human trialLinaclotide should be administered orally on an empty stomach, at least 30 minutes prior to first meal of the day9

  • human trialLinaclotide is administered daily with a once-a-day dosage regimen14

  • expert opinionNo dosage adjustments needed for hepatic impairment9

  • expert opinionNo dosage adjustments needed for renal impairment9

  • expert opinionTreatment plan for constipation should be tailored to the severity of the patient's symptoms28

How the body handles it

Based on 8 human trial findings, 1 human study finding, 1 animal finding, 4 expert opinion findings and 1 theoretical finding.

  • human trialSystemic exposure was not noted for linaclotide or its active metabolite in phase 1 studies over a range of doses1

  • human trialSparse sampling following clinically relevant doses of drug in phase 3 clinical trials did not suggest potential for systemic exposure, with exception of couple of patients who had detectable, albeit very low systemic concentrations at couple of time points post-dose1

  • human trialLinaclotide and its active metabolite are not measurable in plasma following administration of the recommended clinical doses1

  • human trialLinaclotide is administered daily with negligible bioavailability following oral administration and a favorable safety profile5

  • human trialLinaclotide active metabolite was found in feces samples about 5% of fasting patients and 3% of fed patients11

  • human trialLINZESS acts locally within the GI tract and has negligible systemic availability12

  • human trialSystemic exposure of drug and active metabolite are negligible following oral administration12

  • human trialLinaclotide has negligible bioavailability following oral administration14

Show the remaining 7

  • human studyLinaclotide has a first-order half-life of only 3 minutes6

  • animalLinaclotide acts locally in the GI tract with minimal systemic exposure, resulting in low oral bioavailability13

  • expert opinionLinaclotide is minimally absorbed which creates very low systemic bioavailability11

  • expert opinionPharmacokinetic parameters such as AUC, Cmax, Tmax, half-life cannot be calculated11

  • expert opinionMetabolized within the intestinal lumen (GI tract) into its active metabolite by losing its terminal tyrosine moiety11

  • expert opinionBoth linaclotide and its active metabolite are proteolytically degraded into smaller peptides and amino acids11

  • theoreticalDue to lack of measurable plasma concentrations, distribution to the tissue is theoretically minimal11

Safety and side effects

Based on 21 human trial findings, 5 human study findings, 8 animal findings, 1 expert opinion finding and 1 theoretical finding.

  • human trialPatients may experience severe diarrhea with LINZESS; if severe diarrhea occurs, suspend dosing and rehydrate the patient2

  • human trialMost common adverse reactions (≥2%) in adult patients with IBS-C or CIC are diarrhea, abdominal pain, flatulence and abdominal distension2

  • human trialMost common adverse reaction (≥2%) in pediatric patients 7 to 17 years with IBS-C and 6 to 17 years with FC is diarrhea2

  • human trialMost common adverse reactions in adult patients with IBS-C or CIC are diarrhea, abdominal pain, flatulence and abdominal distension3

  • human trialMost common adverse reaction in pediatric patients 7 to 17 years of age with IBS-C and 6 to 17 years of age with FC is diarrhea3

  • human trialPatients may experience severe diarrhea; if severe diarrhea occurs, suspend dosing and rehydrate the patient3

  • human trialLINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction3

  • human trialInfrequent adverse events linaclotide were observed in clinical trials6

Show the remaining 28

  • human trialThis medicine should not be used in children younger than 2 years of age because it may increase the risk of serious dehydration8

  • human trialSafety and efficacy have not been established in children younger than 2 years of age to treat functional constipation and in children younger than 7 years of age to treat IBS-C8

  • human trialAdverse drug events appear to be a bigger concern (diarrhea) than the actual difference in improvement in abdominal pain and constipation11

  • human trialDiarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials12

  • human trialSevere diarrhea was reported in 2% of adult patients with IBS-C or CIC treated with LINZESS 145 mcg or 290 mcg once daily12

  • human trialSevere diarrhea was reported in <1% of adult patients with CIC treated with LINZESS 72 mcg once daily12

  • human trialIn pediatric patients, diarrhea was reported in 4% of pediatric patients 6 to 17 years of age with FC treated with LINZESS 72 mcg once daily12

  • human trialDiarrhea was reported in 7% and 8% of pediatric patients 7 to 17 years of age with IBS-C treated with LINZESS 145 mcg and 290 mcg once daily, respectively12

  • human trialIn clinical trials, severe diarrhea was reported in one pediatric patient with FC treated with LINZESS 72 mcg once daily and in one pediatric patient with IBS-C treated with LINZESS at a dose higher than the recommended 145 mcg once daily dosage for IBS-C12

  • human trialCommon adverse reactions in IBS-C or CIC adult patients include diarrhea, abdominal pain, flatulence, and abdominal distension12

  • human trialCommon adverse reaction in FC or IBS-C pediatric patients is diarrhea12

  • human trialThe most frequent side effect of linaclotide is diarrhoea, which results from the therapeutic action13

  • human trialLinaclotide has a favorable safety profile14

  • human studyDiarrhea may occur with linaclotide, generally within first 2 weeks of therapy9

  • human studySevere diarrhea reported in 2% of patients receiving linaclotide 145 or 290 mcg daily and in <1% of those receiving 72 mcg daily9

  • human studySevere diarrhea associated with dizziness, syncope, hypotension, and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or IV fluids has been reported9

  • human studyLinaclotide is contraindicated in infants and children <6 years of age; avoid use in children and adolescents 6 to <18 years of age9

  • human studySafety and efficacy not established in patients <18 years of age9

  • animalAge- and dose-related mortality was noted in juvenile mice dosed with linaclotide1

  • animalLINZESS is contraindicated in patients less than 2 years of age due to risk of serious dehydration2

  • animalIn neonatal mice, linaclotide caused deaths due to dehydration2

  • animalLINZESS is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, linaclotide caused deaths due to dehydration3

  • animalSingle, clinically relevant, oral adult dose caused deaths due to dehydration in neonatal mice9

  • animalLINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration12

  • animalIn neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration12

  • animalIn neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration12

  • expert opinionLINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction2

  • theoreticalLinaclotide treatment has the potential to induce diarrhea by boosting CFTR activity23

What people use it for

Based on 19 human trial findings, 9 human study findings, 2 animal findings, 27 expert opinion findings and 1 theoretical finding.

  • human trialLINZESS is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older2

  • human trialLINZESS is indicated for treatment of chronic idiopathic constipation (CIC) in adults2

  • human trialLINZESS is indicated for treatment of functional constipation (FC) in pediatric patients 2 years of age and older2

  • human trialLINZESS is a guanylate cyclase-C agonist indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older3

  • human trialLINZESS is indicated for chronic idiopathic constipation (CIC) in adults3

  • human trialLINZESS is indicated for functional constipation (FC) in pediatric patients 2 years of age and older3

  • human trialLinaclotide is indicated for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC)4

  • human trialLinaclotide is FDA-approved for adults suffering from irritable bowel syndrome with predominant constipation (IBS-C) and chronic idiopathic constipation (CIC)5

Show the remaining 50

  • human trialLinaclotide is used to treat irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation8

  • human trialLinaclotide is indicated for symptomatic treatment of irritable bowel syndrome (IBS) with constipation in adults9

  • human trialLinaclotide is indicated for symptomatic treatment of chronic idiopathic constipation in adults9

  • human trialLINZESS is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older12

  • human trialLINZESS is indicated for the treatment of chronic idiopathic constipation (CIC) in adults12

  • human trialLINZESS is indicated for the treatment of functional constipation (FC) in pediatric patients 6 years of age and older12

  • human trialLinaclotide is FDA-approved for irritable bowel syndrome with predominant constipation (IBS-C)14

  • human trialLinaclotide is FDA-approved for chronic idiopathic constipation (CIC)14

  • human trialLinaclotide is a secretagogue agent for treatment of chronic idiopathic constipation (CIC)16

  • human trialLinaclotide is a secretagogue agent for pharmacological treatment of chronic idiopathic constipation (CIC) in adults17

  • human trialLinaclotide was included in a network meta-analysis comparing efficacy of drugs in adults with chronic idiopathic constipation19

  • human studyLinaclotide can manage refractory lower gastrointestinal manifestations in patients with systemic sclerosis5

  • human studyNearly 15% of the US population meet the criteria for chronic constipation10

  • human study12% of the US population meet the criteria for irritable bowel syndrome10

  • human studyLinaclotide 290 μg has been approved by the European Medicines Agency (EMA) for moderate-to-severe IBS-C13

  • human studyLinaclotide has been approved by the US Food and Drug Administration for IBS-C (290 μg dose) and for chronic constipation (145 μg dose)13

  • human studyLinaclotide shows promise in managing refractory lower GI manifestations in systemic sclerosis patients14

  • human studyLinaclotide can alleviate constipation induced by opioid use14

  • human studyLinaclotide is a new pharmacological agent for treatment of functional constipation15

  • human studyLinaclotide is a prosecretory agent indicated for treatment of chronic idiopathic constipation in patients not responding to traditional laxatives20

  • animalAnimal models have suggested that linaclotide may ameliorate visceral hypersensitivity23

  • animalLinaclotide's impact on cGMP/PKG activity in the colonic epithelium has potential for prevention of CRC carcinogenesis demonstrated in rodent models23

  • expert opinionLinaclotide is a 14-amino acid GC-C agonist intended for treatment of Chronic Idiopathic Constipation (CIC) and IBS-constipation in adults1

  • expert opinionIBS is the most commonly diagnosed GI disorder, with an estimated prevalence rate of 7% in North America7

  • expert opinionThe estimated prevalence of CIC in North America is 14%, with higher rates in women and the elderly7

  • expert opinionChronic constipation and IBS-C both present with infrequent bowel movements, hard stools, a sensation of incomplete evacuation, rectal pressure or pain, straining, and occasional need for evocative or manual maneuvers to evacuate stool10

  • expert opinionIBS-C includes lower abdominal pain that is associated with defecation and is temporally related to a change in stool form or frequency10

  • expert opinionLinaclotide was developed for treatment of chronic constipation and constipation-predominant IBS in patients with persistent symptoms despite dietary modification, exercise, or use of over-the-counter medications10

  • expert opinionLabeled uses include Chronic constipation (Idiopathic) and Irritable bowel syndrome associated with constipation11

  • expert opinionLinaclotide can alleviate constipation induced by diabetes mellitus14

  • expert opinionLinaclotide can alleviate constipation induced by neurological conditions14

  • expert opinionLinaclotide can alleviate constipation induced by post-surgery complications14

  • expert opinionLinaclotide is a secretagogue recommended for treatment of chronic constipation18

  • expert opinionLinaclotide is a newer agent suitable for treating slow-transit constipation22

  • expert opinionLinaclotide is a secretagogue that may be used in the treatment of functional bloating and abdominal distension25

  • expert opinionLinaclotide is one of several drugs with new mechanisms of action that have been introduced as treatments for chronic constipation26

  • expert opinionMedical therapy for chronic constipation includes osmotic laxatives, secretagogues, bile acid transporter inhibitors, probiotics, prokinetics, and Kampo medicines26

  • expert opinionIrritable bowel syndrome is characterized by abdominal pain, bloating and abdominal distention and altered bowel movements, with a predominance of diarrhoea, constipation, or alternation of these signs27

  • expert opinionIBS disease affects 5%-10% of healthy individuals at any given time27

  • expert opinionIBS in most people has a relapsing-remitting course27

  • expert opinionTherapeutic options for IBS include dietary, pharmacological and psychotherapeutic interventions27

  • expert opinionChronic constipation affects one-third of the US population28

  • expert opinionChronic constipation occurs disproportionately in the elderly and female individuals28

  • expert opinionChronic constipation increases in older individuals who are institutionalized28

  • expert opinionChronic constipation has a significant impact on health care costs and quality of life28

  • expert opinionThe cause of constipation in elderly individuals is often multifactorial28

  • expert opinionPelvic floor dysfunction is more common in older individuals with constipation28

  • expert opinionIf symptoms do not improve, a trial of linaclotide or lubiprostone may be appropriate29

  • expert opinionLinaclotide is used as a treatment option for constipation after lifestyle modifications and initial pharmacological interventions have been attempted29

  • theoreticalLinaclotide is approved for treatment of constipation-type irritable bowel syndrome23

Other findings

Based on 1 human trial finding and 5 expert opinion findings.

  • human trialFDA approved linaclotide on August 30, 20125

  • expert opinionInitial U.S. Approval was in 20122

  • expert opinionLubiprostone was approved in 2008 for the treatment of IBS–C in women 18 years of age and older and for the treatment of CIC in adults7

  • expert opinionTegaserod was approved in 2002 for the short-term treatment of IBS–C in women and in 2004 for the treatment of CIC in adults 65 years of age or younger7

  • expert opinionFDA approved linaclotide on August 30, 201214

  • expert opinionIBS-C and CIC affect approximately 20% of the general population14

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Pediatric efficacy evidence is limited

One review notes that to date there are no placebo-controlled trials published on the use of linaclotide or lubiprostone in children, and a database source states safety and efficacy are not established in patients under 18 years, despite regulatory pediatric indications.

Limited evidence

Several proposed uses rest on animal or early-stage evidence only

Claims about brown fat thermogenesis/energy expenditure, colorectal cancer prevention, TMAO reduction, and cystic fibrosis GI transit are based on animal, in vitro, or theoretical evidence, not human clinical trials.

Other

Diarrhea benefit-risk tension noted

One review-style source suggests that adverse drug events (diarrhea) may be a bigger concern than the actual magnitude of improvement in abdominal pain and constipation, whereas regulatory and other reviews characterize the safety profile as favorable.

Using it with other compounds

Check a stack
  • SemaglutideComplementary

    Worth caution

    GLP-1 agonists like semaglutide slow gastric emptying and commonly cause constipation, whereas linaclotide accelerates gut transit and softens stool. In practice linaclotide can counteract GLP-1-induced constipation, so the two have opposing effects on motility that can offset one another. Watch stool consistency: too much fluid secretion plus altered emptying can tip toward diarrhea or cramping.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims the peptides have 'complementary' effects based on opposing impacts on gut motility (semaglutide slowing gastric emptying vs. linaclotide accelerating transit). However, the provided mechanism descriptions do not establish this relationship. Semaglutide's mechanism material lists 'Delayed gastric emptying' as an effect but provides no mechanistic detail about how this occurs or its relationship to constipation. Linaclotide's mechanisms clearly describe acceleration of intestinal/colonic transit and increased fluid secretion via GC-C/cGMP/CFTR pathways. While the explanation invokes real-world clinical observations about GLP-1-induced constipation and linaclotide's counteracting potential, these observations are not grounded in the provided mechanism descriptions themselves. The mechanisms do not explicitly connect semaglutide's delayed gastric emptying to constipation, nor do they establish a mechanistic basis for why linaclotide would specifically counteract GLP-1 effects. The relationship is plausible from external pharmacology knowledge but is not justified by the mechanism material provided.

    Timing Monitor bowel response; adjust linaclotide dose to GI symptoms.

  • TirzepatideComplementary

    Worth caution

    Like other incretin agonists, tirzepatide slows gastric emptying and frequently causes constipation; linaclotide does the opposite by boosting intestinal fluid secretion and transit, so it can relieve incretin-related constipation. Their opposing GI effects can balance out, but combined they need monitoring to avoid swinging into diarrhea or dehydration.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims complementary opposing GI effects, but the mechanism descriptions do not establish this as a justified pharmacological relationship. While tirzepatide's mechanism does mention 'slowed gastric emptying,' the descriptions do not explicitly state that tirzepatide causes constipation as a direct mechanistic consequence. Linaclotide's mechanisms clearly show increased fluid secretion and accelerated transit. However, the claim that these peptides have 'complementary' mechanisms that 'balance out' relies on external pharmacological knowledge (that incretin agonists cause constipation) rather than being directly supported by the provided mechanism material. The explanation invokes clinical experience and side-effect profiles not present in the mechanism descriptions. Additionally, no shared dimensions are claimed, which further undermines the relationship characterization. The mechanisms describe distinct receptor targets, distinct signaling pathways (cGMP/PKG for linaclotide vs. cAMP/β-arrestin for tirzepatide), and distinct primary effects, without the descriptions themselves establishing a complementary mechanistic relationship.

    Timing Titrate linaclotide against constipation symptoms and monitor for diarrhea.

  • PlecanatideSame mechanism

    Research does not support combining these

    Plecanatide and linaclotide are both guanylate cyclase-C (GC-C) agonists that drive the exact same cGMP/CFTR pathway to pull fluid into the gut and speed transit. Stacking them is redundant rather than additive, and combining two secretagogues would sharply raise the risk of watery diarrhea, dehydration and electrolyte loss. If you need a GC-C agonist, pick one — do not run both.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish the same primary pathway: GC-C receptor agonism → cGMP signaling → CFTR-mediated chloride/bicarbonate secretion → increased intestinal fluid secretion and accelerated transit. Linaclotide targets GC-C and activates cGMP/PKG/CFTR pathways; plecanatide targets GC-C and activates cGMP/CFTR pathways. Both produce overlapping clinical effects (increased fluid secretion, accelerated transit, improved bowel movements, reduced bloating). The mechanism descriptions support the claim that they engage the same downstream effector cascade, making redundancy and additive risk of adverse effects (watery diarrhea, dehydration) mechanistically justified. The 'same_mechanism' relationship is directly supported by the provided material.

    Timing Do not co-administer; choose one GC-C agonist.

Safety and side effects

Safety and Side Effects

Common adverse reactions

The most common adverse reactions in adults with IBS-C or CIC are diarrhea, abdominal pain, flatulence, and abdominal distension. In pediatric patients, the most common reaction is diarrhea. Diarrhea is a direct consequence of the drug's therapeutic secretory action and generally appears within the first 2 weeks of therapy.

Severe diarrhea

Severe diarrhea was reported in about 2% of adults receiving 145 or 290 mcg daily and in <1% of those receiving 72 mcg daily. Severe diarrhea has been associated with dizziness, syncope, hypotension, and electrolyte abnormalities (hypokalemia and hyponatremia) requiring hospitalization or IV fluids. If severe diarrhea occurs, dosing should be suspended and the patient rehydrated.

In pediatric patients, diarrhea was reported in 4% of FC patients 6–17 years (72 mcg) and in 7% and 8% of IBS-C patients 7–17 years (145 mcg and 290 mcg, respectively); severe diarrhea occurred in one FC patient and one IBS-C patient (the latter at higher than the recommended dose).

Contraindications

  • Patients under 2 years of age — contraindicated due to risk of serious dehydration. In neonatal mice, a single clinically relevant adult oral dose caused deaths from dehydration due to age-dependent elevated GC-C agonism, with increased mortality within the first 24 hours.
  • Known or suspected mechanical gastrointestinal obstruction.

One database source additionally states linaclotide is contraindicated in children under 6 and that use should be avoided in those 6 to under 18, characterizing safety and efficacy as not established under 18 (sources disagree on pediatric age thresholds).

Overall profile

Regulatory and review sources characterize linaclotide as having a favorable safety profile with infrequent adverse events in clinical trials, without associated serious adverse events in chronic constipation evidence. However, one review-style source raises a benefit–risk tension, suggesting that diarrhea may be a greater concern relative to the magnitude of improvement in abdominal pain and constipation.

Reconstitution and handling

Preparation and Administration

Linaclotide is an oral capsule — it does not require reconstitution. It is taken once daily, on an empty stomach at least 30 minutes before the first meal (breakfast) of the day, at approximately the same time each day. The capsule (or its contents) should not be crushed or chewed; swallow the capsule whole.

Dosing

  • IBS-C, adults: 290 mcg orally once daily.
  • CIC, adults: 145 mcg orally once daily, or 72 mcg once daily based on individual presentation or tolerability.
  • IBS-C, pediatric patients 7 years and older: 145 mcg orally once daily.
  • FC, pediatric patients 2 years and older: 72 mcg orally once daily.

For chronic idiopathic constipation, a higher dose (290 mcg daily) is not associated with additional clinical benefit.

Special Populations

  • No dosage adjustment is needed for hepatic or renal impairment.
  • Linaclotide lacks typical characteristics of a molecule likely to be taken up into maternal milk (high maternal plasma concentrations, lipid solubility, low molecular weight), consistent with its negligible systemic absorption.

Pharmacokinetic Notes

Linaclotide has very low oral bioavailability and acts locally in the GI tract with minimal systemic exposure. It and its active metabolite are generally not measurable in plasma at recommended doses, so standard PK parameters (AUC, Cmax, Tmax, half-life) cannot be reliably calculated; one source reports a first-order half-life of ~3 minutes. It is metabolized within the intestinal lumen to its active metabolite by loss of its terminal tyrosine, with both further degraded to smaller peptides and amino acids; the active metabolite was recovered in feces of about 5% of fasting and 3% of fed patients.

Sources

Ordered by evidence quality — the strongest first.

  1. 202811Orig1s000 - accessdata.fda.gov(opens in a new tab)
    Tier 1Web · accessdata.fda.gov
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION(opens in a new tab)
    Tier 1Web · dailymed.nlm.nih.gov
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION ---------------------DOSAGE FORMS AND STRENGTHS---------------------- Capsules: 72 mcg, 145 mcg and 290 mcg (3)(opens in a new tab)
    Tier 1Web · rxabbvie.com
  4. Linaclotide(opens in a new tab)
    Tier 1Web · go.drugbank.com
  5. Linaclotide - StatPearls - NCBI Bookshelf(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  6. Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  7. Linaclotide (Linzess) for Irritable Bowel syndrome With Constipation ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  8. Linaclotide (oral route) - Side effects & dosage - Mayo Clinic(opens in a new tab)
    Tier 1Web · mayoclinic.org
  9. Linaclotide Monograph for Professionals - Drugs.com(opens in a new tab)
    Tier 1Web · drugs.com
  10. Linaclotide: A Novel Therapy for Chronic Constipation and ...(opens in a new tab)
    Tier 1Web · gastroenterologyandhepatology.net
  11. Linzess Generic Name: linaclotide Manufacturer: Forest Laboratories, ...(opens in a new tab)
    Tier 1Web · pharmacy.hsc.wvu.edu
  12. Mechanism of Action in CIC | LINZESS® (linaclotide)(opens in a new tab)
    Tier 1Web · linzesshcp.com
  13. Review article: linaclotide for the management of irritable bowel syndrome with constipation(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  14. Linaclotide - StatPearls - NCBI - NIH(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov · 2024
  15. 2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  16. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  17. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  18. European society of neurogastroenterology and motility guidelines on functional constipation in adults.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  19. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2019
  20. Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  21. Gastrointestinal Pharmacology.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2017
  22. Diagnosis and management of chronic constipation in adults.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  23. Linaclotide - an overview | ScienceDirect Topics(opens in a new tab)
    Tier 2Web · sciencedirect.com
  24. Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation(opens in a new tab)
    Tier 2Web · jpet.aspetjournals.org
  25. European Consensus on Functional Bloating and Abdominal Distension-An ESNM/UEG Recommendations for Clinical Management.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  26. Management of Chronic Constipation: A Comprehensive Review.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  27. Irritable bowel syndrome.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  28. Evaluation and Treatment of Constipation in the Geriatric Population.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  29. Management of Constipation in Older Adults.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2015